GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rezolute Inc (NAS:RZLT) » Definitions » 10-Year RORE %

RZLT (Rezolute) 10-Year RORE % : -17.21% (As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Rezolute 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Rezolute's 10-Year RORE % for the quarter that ended in Sep. 2024 was -17.21%.

The industry rank for Rezolute's 10-Year RORE % or its related term are showing as below:

RZLT's 10-Year RORE % is ranked worse than
68.98% of 590 companies
in the Biotechnology industry
Industry Median: -6.205 vs RZLT: -17.21

Rezolute 10-Year RORE % Historical Data

The historical data trend for Rezolute's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rezolute 10-Year RORE % Chart

Rezolute Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.20 -18.72 -27.84 -15.93

Rezolute Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.53 -27.68 -15.28 -15.93 -17.21

Competitive Comparison of Rezolute's 10-Year RORE %

For the Biotechnology subindustry, Rezolute's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rezolute's 10-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rezolute's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Rezolute's 10-Year RORE % falls into.



Rezolute 10-Year RORE % Calculation

Rezolute's 10-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -1.27--28 )/( -155.34-0 )
=26.73/-155.34
=-17.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 10-year before.


Rezolute  (NAS:RZLT) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Rezolute 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Rezolute's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rezolute Business Description

Traded in Other Exchanges
N/A
Address
275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Executives
Wladimir Hogenhuis director 60 LEVERONI COURT, NOVATO CA 94949
Brian Kenneth Roberts officer: Chief Medical Officer C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Young-jin Kim director 49, BONGEUNSA-RO 49-GIL, GANGNAM-GU, SEOUL M5 06100
Nevan C Elam director, 10 percent owner, officer: Chief Executive Officer C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Handok, Inc. 10 percent owner 132, TEHERAN-RO, GANGNAM GU, SOUL M5 06235
Gil M Labrucherie director 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Nerissa Kreher director C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Philippe Fauchet director C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Junghee Lim director C/O REZOLUTE, INC., 201 REDWOOD SHORE'S PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Genexine Inc. 10 percent owner 700 DAEWANGPANGYO-RO, KOREA PARKBLDG. B, BUNDANG-GU, SEONGNAM-SI, GYEONGGI-DO M5 13488
Seline E. Miller officer: VP Finance & CAO C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Young Chul Sung director 101DONG 404HO, PARKTOWER APT. 69, SEOBINGGO-RO, YONGSAN-GU, SEOUL M5 04385
Keith A. Vendola officer: Chief Financial Officer 111 LIVORNO WAY, REDWOOD CITY CA 94065
Xoma Corp 10 percent owner 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
David F Welch director C/O INFINERA CORPORATION, 140 CASPIAN COURT, SUNNYVALE CA 94089